BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
LLY upcoming catalysts
Eli Lilly and Company: 4 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (1 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 37 readout(s) and 16 FDA event(s). Subscribe to LLY (.ics).
Drugs: Tirzepatide, Retatrutide, Orforglipron, Abemaciclib, Temozolomide, Brenipatide, Tocilizumab, Semaglutide, Insulin Glargine
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No upcoming PDUFA date or AdCom found. | |||||
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P2 | Eli Lilly and Company LLY | NCT07169851 A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer | Nausea; Vomiting; Drug-Related Side Effects and Adverse Reactions; Neoplasms | recruiting | 204 |
| 2027-02 est. | P2 | Eli Lilly and Company LLY | NCT06413706 A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy | Glioma | active not recruiting | 45 |
| 2027-02 est. | P3 | Eli Lilly and Company LLY | NCT06672549 A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | Obesity; Overweight | recruiting | 125 |
| 2027-02 est. | P2 | Eli Lilly and Company LLY | NCT07223840 A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse | Smoking | recruiting | 222 |
FDA decision events, last 12 months
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11 est. | P2 | Eli Lilly and Company LLY | NCT07511816 A Study of LY4515100 in Participants With Pain Following Third Molar Removal | Acute Pain; Molar; Molar, Third; Surgery, Oral | recruiting | 212 |
| 2026-11 est. | P2 | Eli Lilly and Company LLY | NCT07215312 A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin | Diabetes Mellitus, Type 2 | active not recruiting | 100 |
| 2026-11 est. | P3 | Eli Lilly and Company LLY | NCT06962280 A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | Type 1 Diabetes; Obesity; Overweight | active not recruiting | 465 |
| 2026-11 est. | P3 | Eli Lilly and Company LLY | NCT06914895 A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | Type 1 Diabetes; Obesity; Overweight | active not recruiting | 905 |
| 2026-11 est. | P3 | Eli Lilly and Company LLY | NCT06662383 A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity | Obesity | active not recruiting | 800 |
| 2026-10-26 | P3 | Eli Lilly and Company LLY | NCT06297603 Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Ba | Type 2 Diabetes | active not recruiting | 341 |
| 2026-10-22 | P3 | Eli Lilly and Company LLY | NCT06339008 A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1) | Perennial Allergic Rhinitis (PAR) | active not recruiting | 450 |
| 2026-10 est. | P3 | Eli Lilly and Company LLY | NCT04088396 A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA) | Systemic Juvenile Idiopathic Arthritis | active not recruiting | 58 |
| 2026-08-27 | P3 | Eli Lilly and Company LLY | NCT06260722 Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 | Diabetes Mellitus, Type 2 | active not recruiting | 1250 |
| 2026-08-03 | P2 | Eli Lilly and Company LLY | NCT06598943 A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis | Ulcerative Colitis; Ulcerative Colitis Chronic | active not recruiting | 143 |
| 2026-07-21 | P3 | Eli Lilly and Company LLY | NCT06649045 A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight | OSA; Overweight or Obesity | completed | 712 |
| 2026-07-06 | P2 | Eli Lilly and Company LLY | NCT05536804 A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes | Overweight; Obesity; Chronic Kidney Disease; Type 2 Diabetes; T2D | completed | 134 |
| 2026-07-01 | P2 | Eli Lilly and Company LLY | NCT06603571 A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight W | Obesity; Overweight | completed | 367 |
| 2026-06-16 | P3 | Eli Lilly and Company LLY | NCT05929079 A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight | Type 2 Diabetes; Obesity; Overweight; Obstructive Sleep Apnea | completed | 1152 |
| 2026-06-02 | P3 | Eli Lilly and Company LLY | NCT06075667 A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities | Obesity; Overweight | active not recruiting | 160 |
| 2026-05-13 | P3 | Eli Lilly and Company LLY | NCT06921759 A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis | Atopic Hand and Foot Dermatitis | completed | 221 |
| 2026-05-01 | P2 | Eli Lilly and Company LLY | NCT06538116 A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease | Alzheimer Disease | completed | 304 |
| 2026-05-01 | P3 | Eli Lilly and Company LLY | NCT05784246 A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis | Ulcerative Colitis | completed | 63 |
| 2026-04-16 | P3 | Eli Lilly and Company LLY | NCT05882045 A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease | Obesity; Cardiovascular Diseases | completed | 1946 |
| 2026-04-06 | P3 | Eli Lilly and Company LLY | NCT05929066 A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight | Obesity; Overweight; Osteoarthritis, Knee; Obstructive Sleep Apnea | completed | 2335 |
| 2026-03-19 | P2 | Eli Lilly and Company LLY | NCT06817356 A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder | Alcohol Use Disorder | completed | 308 |
| 2026-03-16 | P3 | Eli Lilly and Company LLY | NCT05803421 A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardio | Type 2 Diabetes; Obesity; Overweight or Obesity; Overweight; Cardiovascular Diseases; Chronic Kidney | completed | 2749 |
| 2026-03-04 | P3 | Eli Lilly and Company LLY | NCT03519945 A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) | Ulcerative Colitis | active not recruiting | 1058 |
| 2026-01-22 | P3 | Eli Lilly and Company LLY | NCT06354660 Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T | Diabetes Type 2 | completed | 537 |
| 2026-01-20 | P3 | Eli Lilly and Company LLY | NCT06047548 A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities | Overweight; Obesity | completed | 441 |
| 2026-01-16 | P2 | Eli Lilly and Company LLY | NCT06643728 A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight | Obesity; Overweight | completed | 252 |
| 2026-01-14 | P3 | Eli Lilly and Company LLY | NCT05559359 A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis | Atopic Dermatitis; Eczema | active not recruiting | 377 |
| 2026-01-12 | P2 | Eli Lilly and Company LLY | NCT06568042 Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy | Neuropathic Pain; Distal Sensory Polyneuropathy | completed | 558 |
| 2026-01-12 | P3 | Eli Lilly and Company LLY | NCT04819100 A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) | Carcinoma, Non-Small-Cell Lung | active not recruiting | 152 |
| 2026-01-08 | P3 | Eli Lilly and Company LLY | NCT06588283 Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight | Psoriasis; Obesity | completed | 281 |
| 2026-01-08 | P2 | Eli Lilly and Company LLY | NCT06037252 A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity | Type 2 Diabetes; Obesity | active not recruiting | 414 |
| 2026-01-07 | P2 | Eli Lilly and Company LLY | NCT06683508 A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight | Obesity; Overweight | completed | 288 |
| 2025-12-15 | P2 | Eli Lilly and Company LLY | NCT06373146 A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity | Obesity | completed | 392 |
| 2025-12-10 | P3 | Eli Lilly and Company LLY | NCT04616326 A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine | Chronic Migraine | active not recruiting | 312 |
| 2025-12-08 | P2 | Eli Lilly and Company LLY | NCT05848258 An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis | Rheumatoid Arthritis | completed | 164 |
| 2025-12-04 | P3 | Eli Lilly and Company LLY | NCT04396574 A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine | Migraine | terminated | 558 |
| 2025-11-21 | P3 | Eli Lilly and Company LLY | NCT06584916 A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MA | Obesity; Overweight | completed | 376 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.